DiscoverIPO

Neuro Spectrum Insights, Inc.

expected
Not yet set
status
Filed with SEC
Industry
Surgical & Medical Instruments & Apparatus
Headquarters
United States
Incorporated in
DE
Underwriters (from filing)
Network 1

Overview

— AI-generated from the filing, see note below

Business overview

Neuro Spectrum Insights, Inc. is a medical device company focused on commercializing a patented software solution named GyriCalc™, designed to assist in diagnosing autism by analyzing MRI images for structural markers. Although GyriCalc has received FDA 510(k) marketing clearance, it has not yet received FDA clearance for diagnostic use. The company currently does not generate revenue and seeks to launch GyriCalc in U.S. and Canadian markets, emphasizing strategic partnerships and reimbursement mechanisms for market penetration.

Revenue model

Neuro Spectrum Insights, Inc. does not currently generate revenue as it is in the commercialization phase of its product, GyriCalc. The company aims to establish market access strategies focusing on partnerships and government discussions for reimbursement.

Last FY net loss
$2M

Competitive strengths

  • Proprietary software technology with FDA 510(k) clearance
  • Potential to significantly shorten the diagnostic process for autism
  • Exclusive licensing agreement with a reputable academic institution (University of Louisville)
  • Innovative approach utilizing existing MRI technology

Risk factors

  • No current revenue generation
  • Dependence on successful commercialization of GyriCalc
  • Potential regulatory hurdles in the diagnostic use of GyriCalc
  • Competitive pressures from other diagnostic solutions in the market
  • Investment in technology and market entry is capital intensive and risky

Use of proceeds

Proceeds from the offering will be used to fund working capital and general corporate purposes, which may include product development, marketing, and other operational needs.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Underwriters on the deal include Network 1. Neuro Spectrum Insights, Inc. is headquartered in United States and incorporated in DE. It is classified under Surgical & Medical Instruments & Apparatus.

Neuro Spectrum Insights, Inc. has filed 2 times, starting with a S1/A on Jul 10, 2026.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Neuro Spectrum Insights, Inc..

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/neuro-spectrum-insights" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Neuro Spectrum Insights, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/neuro-spectrum-insights?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/neuro-spectrum-insights/opengraph-image

Attribution text

Neuro Spectrum Insights, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/neuro-spectrum-insights?utm_source=embed&utm_medium=text&utm_campaign=neuro-spectrum-insights

Track this IPO

Get emailed when Neuro Spectrum Insights, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Jul 31, 2026.

View the original filing on SEC EDGAR

Filing amendment history

How this offering's SEC filings changed over time. Only SEC-sourced filings carry a full amendment history to compare; other regulators publish a single filing with no prior version to diff against.

  1. S1/A filed Jul 10, 2026

    Initial filing.

  2. S1/A filed Jul 30, 2026

    No tracked deal terms changed in this amendment.

All filings for this company

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.

We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy